| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 209.7 | 139.4 | 138.5 |
| Other income | 4.2 | 2.6 | 3.4 |
| Total income | 213.8 | 142.0 | 142.0 |
| Profit before exceptional items & tax | 34.2 | 24.1 | 24.3 |
| Profit before tax | 34.2 | 24.1 | 24.3 |
| Net profit | 25.8 | 18.1 | 16.6 |
| Operating margin | 16.0% | 17.0% | 17.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +55.40% |
|---|---|
| Net profit, quarter on quarter | +42.50% |
| Revenue, year on year | +51.40% |
NSE results filing, NSE: ACCENTMIC. Figures extracted from the filing.
Accent Microcell Ltd: key numbers
- Share price
- ₹674.85
- Market cap
- ₹1,619 Cr
- Revenue (annual)
- ₹349.0 Cr
- Net profit (annual)
- ₹43.86 Cr
- P/E (TTM)
- 36.9×Sector 50.4×
- Promoter holding
- 53.02%-2.45% QoQ
- FII holding
- 0.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accent Microcell Ltd
All →Accent Microcell Earnings Call: Key Takeaways
Accent Microcell transcript for FY26 results highlights growth driven by high-value premium products (MCC spheres, SMCC) and upcoming capacity expansion via Unit 3.
Accent Microcell Earnings Call: Key Takeaways
Accent Microcell reported FY26 revenue of ₹34,903 Lakhs (up 31.92% YoY) and PAT of ₹4,385 Lakhs (up 32.65% YoY), driven by strong export growth and expansion in pharmaceutical excipients.
Accent Microcell Earnings Call: Key Takeaways
Accent Microcell delivered record H2 results driven by a strategic shift toward premium products like MCC spheres, though Unit 3 delays at Navagam remain a point of concern for immediate scaling.